Skip to content
A1923Assembly2021-2022 SessionSame asS5158

Publish List of Generic Drugs

Official title

“Requires the commissioner of health to establish and publish a list of generic drug products; repealer”

Sponsor Amy PaulinAD-88+6 co-sponsorsAffects Finance
Status
In Assembly Committee
Ways And Means
Impact
6/10
Moderate
Passage
0%

Bill progress

Step 2 of 7

In committee · Ways And Means

What's happening

This bill updates laws regarding generic drug products, requiring the state to publish a list of approved generics and related data.

Why it matters

  1. Increases Transparency and Public Access. By requiring manufacturers to provide detailed data (including bioequivalence, therapeutic equivalence, adverse events, and analytical methods) and mandating the state to publish this information online, the bill aims to make it easier for patients, providers, and pharmacists to assess the quality and safety of generic drugs.

  2. Standardizes Substitution Practices. Updates to prescription and pharmacy laws ensure pharmacists only substitute drugs with generics that meet stricter criteria—specifically, those approved by the FDA as pharmaceutically and therapeutically equivalent, or as interchangeable biologics. This reduces the risk of inappropriate substitutions.

  3. Clarifies Legal Protections for Prescribers. The amendments explicitly protect prescribers from civil liability when they authorize generic drug substitutions in accordance with the updated list, potentially making providers more comfortable with endorsing generics.

  4. Aligns State Practice with Federal Standards. By referencing FDA determinations and excluding drugs flagged for bioequivalence problems, the bill ensures New York’s generic drug list is consistent with current federal safety and efficacy standards, which may help prevent confusion and enhance patient safety.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Publish List of Generic Drugs

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Amy Paulin

Assembly Member · Assembly District 88

Chair, Health

History

  1. Referred to ways and means
  2. Reported referred to ways and means
  3. Referred to health

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

S5158Senate

Publish Generic Drug List

In Senate Committee · Health · Sponsor Andrew J. Lanza

Impact 6 · Moderate0% to pass

Full text

3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

1923

2021-2022 Regular Sessions

IN ASSEMBLY

January 13, 2021

Introduced by M. of A. PAULIN, GOTTFRIED, DINOWITZ, GALEF, J. RIVERA, WEPRIN, ABINANTI -- read once and referred to the Committee on Health

AN ACT to amend the public health law and the education law, in relation to generic drug products; and to repeal paragraph (o) of subdivision 1 of section 206 of the public health law relating thereto

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Paragraph (o) of subdivision 1 of section 206 of the public health law is REPEALED.

§ 2. The public health law is amended by adding a new section 280-d to read as follows:

§ 280-d. Generic drug products. 1. The commissioner shall establish and publish a list of drug products, referred to in this section as "generic drug" products, each of which shall meet the following conditions:

(a) The drug product has been certified or approved by the commissioner of the Federal Food and Drug Administration as being safe and effective for its labeled indications for use, and a new-drug application or an abbreviated new-drug application approved pursuant to the Federal Food, Drug, and Cosmetic Act is held for such drug product; and

(b) The commissioner of the Federal Food and Drug Administration has evaluated such drug product as: (i) pharmaceutically and therapeutically equivalent and has listed such drug product on the list of approved drug products with the therapeutic equivalence evaluations, provided, however, that the list prepared by the commissioner shall not include any drug product which the commissioner of the Federal Food and Drug Administration has identified as having an actual or potential bioequivalence problem or (ii) as an interchangeable biological product and has listed such product on the list of approved drug products with interchangeability.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD01823-01-1

A. 1923 2

2. The manufacturer of a generic drug product shall make available to the department the studies and summaries, including bioequivalence data, therapeutic equivalence data, and incidence of adverse events, and associated analytical methods, including dissolution data and test methods provided to the Federal Food and Drug Administration as part of the application for such generic drug product. The department shall make such information freely and publicly available on its website.

§ 3. Paragraphs (a) and (e) of subdivision 6 of section 6810 of the education law, paragraph (a) as amended by chapter 590 of the laws of 2011 and paragraph (e) as amended by chapter 357 of the laws of 2017, are amended to read as follows:

(a) Every prescription written in this state by a person authorized to issue such prescription shall be on prescription forms containing one line for the prescriber's signature. The prescriber's signature shall validate the prescription. Every electronic prescription shall provide for the prescriber's electronic signature, which shall validate the electronic prescription. Imprinted conspicuously on every prescription written in this state in eight point upper case type immediately below the signature line shall be the words: "THIS PRESCRIPTION WILL BE FILLED GENERICALLY UNLESS PRESCRIBER WRITES 'd a w' IN THE BOX BELOW". Unless the prescriber writes d a w in such box in the prescriber's own handwriting or, in the case of electronic prescriptions, inserts an electronic direction to dispense the drug as written, the prescriber's signature or electronic signature shall designate approval of substitution by a pharmacist of a generic drug product pursuant to [paragraph (o) of subdivision one of] section [two hundred six] two hundred eighty-d of the public health law. No other letters or marks in such box shall prohibit substitution. No prescription forms used or intended to be used by a person authorized to issue a prescription shall have 'd a w' preprinted in such box. Such box shall be placed directly under the signature line and shall be three-quarters inch in length and one-half inch in height, or in comparable form for an electronic prescription as may be specified by regulation of the commissioner. Immediately below such box shall be imprinted in six point type the words "Dispense As Written". Notwithstanding any other provision of law, no state official, agency, board or other entity shall promulgate any regulation or guideline modifying those elements of the prescription form's contents specified in this subdivision. To the extent otherwise permitted by law, a prescriber may modify only those elements of the prescription form's contents not specified in this subdivision. Notwithstanding any other provision of this section or any other law, when a generic drug is not available and the brand name drug originally prescribed is available and the pharmacist agrees to dispense the brand name product for a price that will not exceed the price that would have been charged for the generic substitute had it been available, substitution of a generic drug product will not be required. If the generic drug product is not available and a medical emergency situation, which for purposes of this section is defined as any condition requiring alleviation of severe pain or which threatens to cause disability or take life if not promptly treated, exists, then the pharmacist may dispense the brand name product at his regular price. In such instances the pharmacist must record the date, hour and nature of the medical emergency on the back of the prescription and keep a copy of all such prescriptions.

(e) No prescriber shall be subjected to civil liability arising solely from authorizing, in accordance with this subdivision, the substitution by a pharmacist of a generic drug product pursuant to [paragraph (o) of

A. 1923 3

subdivision one of] section two hundred [six] eighty-d of the public health law.

§ 4. Paragraph (d) of subdivision 6 of section 6810 of the education law, as added by chapter 913 of the laws of 1986, is amended to read as follows:

(d) No prescriber shall be subjected to civil liability arising solely from authorizing, in accordance with this subdivision, the substitution by a pharmacist of a generic drug product pursuant to [paragraph (o) of subdivision one of] section two hundred [six] eighty-d of the public health law.

§ 5. Paragraph (b) of subdivision 1 of section 6816-a of the education law, as added by chapter 776 of the laws of 1977, is amended to read as follows:

(b) The substituted drug product is contained in the list of generic drug products established pursuant to [paragraph (o) of subdivision one of] section [two hundred six] two hundred eighty-d of the public health law; and

§ 6. This act shall take effect on the ninetieth day after it shall have become a law; provided that the amendments to paragraph (e) of subdivision 6 of section 6810 of the education law, made by section three of this act, shall not affect the expiration of such paragraph, when upon such date the provisions of section four of this act shall take effect. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.